17 Jun 2021 Biotalys’ ongoing trial program demonstrates strong potential of its new generation protein-based biocontrols Member news
17 Jun 2021 argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology Member news
16 Jun 2021 Commercial Agency Agreement between Ardena and South Korean company Keyfronbio Co., Ltd. Member news
15 Jun 2021 Biotalys announces intention to launch an Initial Public Offering on Euronext Brussels Member news
14 Jun 2021 Montis Biosciences awarded VLAIO grant to expand its pipeline of novel immune-oncology therapeutics Member news
14 Jun 2021 Precigen ActoBio announces positive topline results from Phase 1b/2a Study of AG019 ActoBiotics™ Member news
10 Jun 2021 OXURION confirms Institutional Review Board approval and submission of the Investigational New Drug Application to the FDA to start Phase 2 Study evaluating THR-687 for Diabetic Macular Edema (DME) Member news
More info? Ellen Telleir Communication Coordinator linkedin.com/in/ellentelleir/ +32 9 241 80 41 ellen.telleir@flanders.bio Contact us
